Sacubitril/valsartan increases postprandial gastrin and cholecystokinin in plasma

• Published in: Endocrine Connections 2020-05, Vol.9 (5), p.438-444
• Main Authors: Andersen, Ulrik Ø, Terzic, Dijana, Wewer Albrechtsen, Nicolai Jacob, Dall Mark, Peter, Plomgaard, Peter, Rehfeld, Jens F, Gustafsson, Finn, Goetze, Jens P
• Format: Article
• Language: English
• Subjects: cholecystokinin; gastrin; heart failure; natriuretic peptide; neprilysin; sacubitril/valsartan
• ISSN: 2049-3614; 2049-3614
• DOI: 10.1530/EC-19-0563

Aims Neprilysin degrades natriuretic peptides in circulation and is also suggested to degrade the gut hormones gastrin and cholecystokinin. Neprilysin inhibition has become a therapeutic strategy and thus a regimen in need of further testing in terms of other hormonal axes besides natriuretic peptides. The aim of this study was to examine whether acute inhibition of neprilysin affects meal-induced responses in gastrin and cholecystokinin concentrations in healthy individuals. Methods and results Nine healthy young men were included in an open-labelled, randomized cross-over clinical trial. The participants received a standardized meal (25 g fat, 26 g protein, 42 g carbohydrate) on two separate days with or without a one-time dosage of sacubitril ((194 mg)/valsartan (206 mg)). Blood pressure, heart rate and blood samples were measured and collected during the experiment. Statistical differences between groups were assessed using area under the curve together with an ANOVA with a Bonferroni post hoc test. Sacubitril/valsartan increased the postprandial plasma concentrations of both gastrin and cholecystokinin (80% (AUC0-270 min, P = 0.004) and 60% (AUC0-270 min, P = 0.003), respectively) compared with the control meal. No significant hemodynamic effects were noted (blood pressure, AUC0-270 min, P = 0.86, heart rate, AUC0-270 min, P = 0.96). Conclusion Our study demonstrates that sacubitril/valsartan increases the postprandial plasma concentrations of gastrin and cholecystokinin in healthy individuals. The results thus suggest that neprilysin-mediated degradation of gastrin and cholecystokinin is physiologically relevant and may have a role in heart failure patients treated with sacubitril/valsartan.